Improving medicines adherence with VRWith medicine adherence still a major problem for pharma and healthcare systems, a collaboration between Cognitant Group and Share XImproving medicines adherence with VRhttps://pharmaphorum.com/views-analysis-digital/improving-medicines-adherence-vr/
Patient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drugUCB/Amgen’s osteoporosis drug Evenity (romosozumab) looks set for approval in Europe after regulators finally recommended it, following a Share XPatient voice overcomes EU ‘no’ for UCB/Amgen’s osteoporosis drughttps://pharmaphorum.com/news/ucb-overcomes-eu-no-for-osteoporosis-drug-with-patient-testimony/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionUCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage Share XUCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionhttps://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/
CHMP says no to Amgen’s osteoporosis drug EvenityAmgen and UCB have suffered another setback as they try to build momentum for Evenity, their new antibody Share XCHMP says no to Amgen’s osteoporosis drug Evenityhttps://pharmaphorum.com/news/chmp-says-no-to-amgens-osteoporosis-drug-evenity/
At long last, Amgen/UCB score FDA okay for EvenityAmgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down Share XAt long last, Amgen/UCB score FDA okay for Evenityhttps://pharmaphorum.com/news/at-long-last-amgen-ucb-score-fda-okay-for-evenity/
Success comes from listening to and working with patientsWith the current mainstay of Parkinson’s treatment being more than 50 years old and doing nothing to slow Share XSuccess comes from listening to and working with patientshttps://pharmaphorum.com/views-analysis-patients/success-comes-from-listening-to-and-working-with-patients/
UCB joins with UK charity to research new epilepsy drugsBelgium’s UCB has joined forces with the UK’s Epilepsy Society in a collaboration aimed at finding treatments for Share XUCB joins with UK charity to research new epilepsy drugshttps://pharmaphorum.com/news/ucb-joins-with-uk-charity-to-research-new-epilepsy-drugs/
Japan approves Amgen’s osteoporosis drugAmgen’s osteoporosis bone-forming drug Evenity (romosozumab) has been approved in Japan, ahead of a crunch review by advisers Share XJapan approves Amgen’s osteoporosis drughttps://pharmaphorum.com/news/japan-approves-amgens-osteoporosis-drug/
